Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novelix Pharmaceuticals Ltd has submitted copies of newspaper publications of its unaudited standalone financial results for the quarter ended 31 December 2025 to BSE, as required under SEBI's Listing Regulations. The results extract was published on 13 February 2026 in two Hyderabad editions: 'The Business Standard' (English) and 'The Nirbhaya Vaartha' (Telugu). This is a routine regulatory compliance filing under Regulation 47 of the SEBI LODR Regulations, 2015. No specific financial numbers (revenue, profit/loss, EPS) are disclosed in this filing — only the fact that the results were published in newspapers. The submission was signed by Whole-time Director Venkateshwarlu Pulluru on 14 February 2026.
This is a procedural compliance filing, not a business update. Investors should look for the actual Q3 FY26 financial results (published in the newspapers) for any meaningful insight into the company's performance. No direct impact on share price is expected from this filing alone.